Ph-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA) Treated with Pediatric Argentine BFM-like Protocol: Real-Word Data on Prognostic Factors and Treatment

FERRARI, LUCIANA; RIVAS, MARÍA M; FERNANDEZ, ISOLDA; SACKMANN, FEDERICO; MELA OSORIO, MARIA JOSE; NAVICKAS, ALICIA; AGAMENNONI, LUCIA; REY, IRENE; AGUERRE, LAURA; DICK, HERNÁN; CARNELUTTO, NATALIA; GOMEZ, MARIELA; CASTRO, MARÍA BELEN; BASQUIERA, ANA L; MOYA, ELIANA; NEGRI ARANGUREN, FLORENCIA; ARANGUREN, PEDRO NEGRI; FISCHMAN, LAURA; COSTA, LUCILA; CAZAP, NICOLÁS; FORNILLO, FLORENCIA; PAGANINI, MARIA; RAPAN, LETICIA; FREUE, JULIAN; CLAVIJO, MANUELA; RAMIREZ, ROXANA; MILONE, JORGE; PAVLOVSKY, MIGUEL ANGEL; BELLI, CAROLINA; MOIRANO, MARÍA

Atlanta

Congreso; 63rd ASH Annual Meeting & Exposition; 2021

American Society of Hematology

Background: ALL in adults is considered a heterogeneous disease with poor prognosis. However, adolescents and young adults (AYA) display intermediate characteristics as compared with children. Risk groups and response predictors are essential to guide the treatment.Aims: The aim of this report was to evaluate the experience of Ph-negative ALL in AYA patients (pts) treated with the pediatric Argentine type-BFM protocol, assessing predictors of response in terms of overall survival (OS) and event-free survival (EFS).Methods: We performed a retrospective multicenter analysis of AYA pts diagnosed between 2013 to 2021, from 16 Argentine institutions who were treated following the pediatric Argentine type-BFM protocol. Response to prednisone (PR) at day(d) 8 (